GS
Gaurav Singh
About Gaurav Singh
Data last updated:
Gaurav Singh is a Director at Meditatav Pharma Private Limited (since 2020). The companies operate in Chemicals and Electrnoics. Meditatav Pharma Private Limited reported revenue of ₹2.2 Lakh (FY 2022). Earlier, Gaurav Singh was a Director at Sachwann Pharma Private Limited (2018–2023).
Current companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 30 Dec 2020 | 2020 | ₹2.2 Lakh (FY 2022) | Active |
Previous companies
| Company | Designation | Appointment | Founded | Revenue | Status |
|---|---|---|---|---|---|
| Director | 04 Jul 2018 | 2018 | ₹2.4 Lakh (FY 2023) | Active |
Explore Director's current and past company associations Uncover their professional journey today!
Board colleagues of Gaurav Singh
| Name | DIN | Company | Designation |
|---|---|---|---|
| Ashish Singh | 09015277 | Meditatav Pharma Private Limited | Director |
| Purushottam Pratap Singh | 09015276 | Meditatav Pharma Private Limited | Director |
Directorship timeline
Open interactive timeline →Shareholding and investment profile for Gaurav Singh
Company-level share counts, filed values, and quarterly changes require authenticated premium access.
- Company-level holdings
- Filed share counts
- Reported values
- Quarterly changes
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Gaurav Singh
Gaurav Singh currently holds 1 directorship: Meditatav Pharma Private Limited (Director, since 30 Dec 2020, revenue ₹2.2 Lakh (FY 2022)).
Gaurav Singh was first appointed on 04 Jul 2018 as Director at Sachwann Pharma Private Limited. The most recent appointment on record is 30 Dec 2020 at Meditatav Pharma Private Limited.
Gaurav Singh held 1 earlier board appointment: Sachwann Pharma Private Limited (Director, 04 Jul 2018 to 06 Nov 2023).
The current boards of Gaurav Singh's companies include Ashish Singh (Meditatav Pharma Private Limited), Purushottam Pratap Singh (Meditatav Pharma Private Limited).